Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 11

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 11
---
3.

#### Operating Profit
As a result of the above factors, Operating Profit was JPY 417.5 billion (JPY +193.4 billion and +86.3% AER, +76.0% CER).

<div align='center'>5</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

#### Net Finance Expenses
Net Finance Expenses were JPY 131.9 billion (JPY +5.4 billion and +4.2% AER, +1.4% CER ). The increase of Net Finance Expenses was primarily due to an impairment loss of JPY 19.4 billion as a result of the classification of Teva Takeda Pharma Ltd. shares to the asset s held for sale for the nine-month period ended December 31, 2024, partially offset by a decrease of net loss from Gains and Losses on Foreign Currency Exchange and Derivative Financial Assets related to Foreign Currency Exchange .

Share of Loss of Investments Accounted for Using the Equity Method

Share of Loss of Investments Accounted for Using the Equity Method was JPY 3.2 billion (JPY +5.9 billion, compared to Share of Profit of Investments Accounted for Using the Equity Method of JPY 2.7 billion for the nine-month period ended December 31, 2023).

#### Income Tax (Expenses) Benefit
Income Tax Expenses were JPY 71.1 billion (JPY +118.0 billion, compared to Income Tax Benefit of JPY 46.9 billion for the nine-month period ended December 31, 2023). The increase was primarily due to a tax expense reduction of JPY 63.5 billion recorded during the nine-month period ended December 31, 2023 resulting from the reversal of the income taxes payable in excess of the settlement with Irish Revenue Commissioners with respect to a tax assessment related to the treatment of an acquisition break fee Shire received from AbbVie in 2014 as well as higher pretax earnings during the nine-month period ended December 31, 2024.

#### Net Profit for the Period
As a result of the above factors, Net Profit for the Period was JPY 211.2 billion ( JPY +64.0 billion and +43.5% AER , +32.0% CER ) and Net